Abstract
We evaluated 52 patients with myelodysplastic syndrome (MDS) who had received at least one red blood cell (RBC) transfusion. In the 4-week period following the first transfusion, 24 patients (group 1) required no transfusion, while 28 (group 2) required transfusion of two or more units of RBCs. Survival was greater in group 1 (440 weeks vs. 167 weeks, p < 0.01), even when only international prognostic scoring system (IPSS) low and intermediate-1 risk patients were analyzed (median overall survival 491 vs. 170 weeks, p < 0.05), independent of age, IPSS and progression to acute myeloid leukemia (AML). The intensity of transfusion required in the first few weeks after the first transfusion predicts disease severity and correlates with survival.
Keywords::
Acknowledgements
We thank Vicki Harris for helpful discussions. This work was supported by a bequest from the estate of the late J. Douglas Crashley and by the Aplastic Anemia and Myelodysplasia Association of Canada. The Sunnybrook MDS Database is supported in part by grants from Celgene Canada and the Canadian Institutes for Health Research.
Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.